Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma

Journal of Clinical Microbiology

Volumn 36, Issue 10, 1998, Pages 2964-2969

  Sun, Rita ^a   Ku, Joanne ^a   Jayakar, Harsha ^a   Kuo, Jo Chi ^a   Brambilla, Donald ^b   Herman, Steven ^a   Rosenstraus, Maurice ^a   Spadoro, Joanne ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ARTICLE; DIAGNOSTIC ACCURACY; HUMAN IMMUNODEFICIENCY VIRUS 1; LABORATORY DIAGNOSIS; NONHUMAN; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS DETECTION; VIRUS DIAGNOSIS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0031656727     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.36.10.2964-2969.1998     Document Type: Article

References (30)

1. BHIVA Guidelines Co-ordinating Committee. 1997. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 349:1086-1092.
2. Carpenter, C. C., M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding for the International AIDS Society-USA. 1996. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. JAMA 276:146-154.
3. Centers for Disease Control and Prevention. 1998. Public Health Service task force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Morbid. Mortal. Weekly Rep. 47 (No. RR-2):1-39.
4. Centers for Disease Control and Prevention. 1998. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Morbid. Mortal. Weekly Rep. 47(No. RR-4):1-51.
5. + cells per cubic millimeter. N. Engl. J. Med. 333:1662-1669.
6. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, and J. A. Chodakewitz. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J, Med. 337:734-739.
7. Hammer, S., C. Crumpacker, R. D'Aquila, B. Jackson, J. Lathey, D. Livnat, and P. Reichelderfer. 1993. Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee. J. Clin. Microbiol. 31:2557-2564.
8. Harris, M., C. Durakovic, S. Rae, J. Raboud, S. Fransen, A. Shillington, B. Conway, and J. S. G. Monaner. 1998. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy. J. Infect. Dis. 177:1514-1520.
9. + lymphocyte count improves assessment of antiretroviral therapeutic response. Ann. Intern. Med. 126:929-938.
10. Izopet, I., G. Salama, C. Pasquier, K. Sandres, E. Kuhlein, A. Blancher, B. Marchou, P. Massip, and J. Puel. 1998. Ultra sensitive detection of plasma HIV-1 RNA for predicting the durability of 3-drug antiretroviral therapy, abstr. 326, p. 140. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Foundation for Retroviruses and Human Health, Alexandria, Va.
11. Kwok, S., and J. J. Sninsky. 1993. PCR detection of human immunodeficiency virus type 1 proviral DNA sequences, p. 309-315. In D. H. Persing, T. F. Smith, F. C. Tenover, and T. J. White (ed.), Diagnostic molecular microbiology: principles and applications. American Society for Microbiology, Washington, D.C.
12. 3. J. Infect. Dis. 177:617-624.
13. Layne, S. P., M. J. Merges, M. Dembo, J. L. Spouge, S. R. Conley, J. P. Moore, J. L. Raina, H. Renz, H. R. Gelderbloom, and P. Nara. 1992. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology 189:695-714.
14. Maeland, A., M. Holberg, J. N. Bruun, and G. Løvgàrden. 1998. Subtle differences in low-level HIV viral load on treatment is important for outcome, abstr. 327, p. 140. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections. Foundation for Retroviruses and Human Health, Alexandria, Va.
15. Mellors, J. W., L. A. Kingsley, C. R. Rinaldo, Jr., J. A. Todd, B. S. Hoo, R. P. Kokka, and P. Gupta. 1995. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. Intern. Med. 122:573-579.
16. Mellors, J. W., C. R. Rinaldo, Jr., P. Gupta, R. M. White, J. A. Todd, and L. A. Kingsley. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170.
17. Mulder, J., R. Resnick, B. Saget, S. Scheibel, S. Herman, H. Payne, R. Harrigan, and S. Kwok. 1997. A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity. J. Clin. Microbiol. 35:1278-1280.
18. 3, abstr. Mo B294, p. 1. In Program and abstracts of the XI International Conference on AIDS. XI International Conference on AIDS Society, Vancouver, British Columbia, Canada.
19. National Committee for Clinical Laboratory Standards. 1992. Evaluation of precision performance of clinical chemistry devices, 2nd ed. Tentative guideline. NCCLS document EP5-T2. National Committee for Clinical Laboratory Standards, Villanova, Pa.
20. + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann. Intern. Med. 126:939-945.
21. + lymphocyte counts and the risk of progression to AIDS. N. Engl. J. Med. 334: 426-431.
22. Office of Public Health and Science, U.S. Department of Health and Human Services. 1997. Guidelines for the use of antiretroviral agents in HIV-infected adults. Fed. Regist. 62:33417-33418.
23. Perelson, A. S., P. Essunger, Y. Cao, M. Vesanen, A. Hurley, K. Saksela, M. Markowitz, and D. D. Ho. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-191.
24. Roche Diagnostic Systems. 1996. AMPLICOR HIV-1-MONITOR test package insert, p. 8-9. Roche Diagnostic Systems, Branchburg, N.J.
25. Saag, M. S., M. Holodniy, D. R. Kuritzkes, W. A. O'Brien, R. Coombs, M. E. Poscher, D. M. Jacobsen, G. M. Shaw, D. D. Richman, and P. A. Volberding. 1996. HIV viral load markers in clinical practice. Nat. Med. 2:625-629.
26. Saksela, K., C. E. Stevens, P. Rubinstein, P. E. Taylor, and D. Baltimore. 1995. HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann. Intern. Med. 123:641-648.
27. Schockmel, G. A., S. Yerly, and L. Perrin. 1997. Detection of low HIV-1 RNA levels in plasma. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 14:179-183.
28. Volberding, P. A. 1996. HIV quantification: clinical applications. Lancet 347: 71-73.
29. Wong, M. T., M. J. Dolan, E. Kozlow, R. Doe, G. P. Melcher, D. S. Burke, R. N. Boswell, and M. Vahey. 1996. Patterns of virus burden and T cell phenotype are established early and are correlated with the rate of disease progression in human immunodeficiency virus type 1-infected persons. J. Infect. Dis. 173:877-887.
30. Yen-Lieberman, B., D. Brambilla, B. Jackson, J. Bremer, R. Coombs, M. Cronin, S. Herman, D. Katzenstein, S. Leung, H. J. Lin, P. Palumbo, S. Rasheed, J. Todd, M. Vahey, and P. Reichelder. 1996. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group Virology Laboratories. J. Clin. Microbiol. 34:2695-2701.